STzen Bio Wins 2 Portions of 2025 Asia-Pacific Biopharmaceuticals CDMO Awards
Sep 12, 2025
|
At the awards ceremony held in Singapore on the 10th (local time), the categories won by Estizen Bio were 'Emerging CDMO of the year' and Best Biologics CDMO Award: Fill-Finish (Best Biopharmaceutical CDMO: Aseptic Charging).
'Emerging CDMO of the year' is an award given to companies with the highest growth potential, and Estizen Bio has been recognized for its outstanding achievements in global GMP approval and strategic cooperation with global pharmaceutical companies to enter major markets such as the United States and Europe.
The 'Best Biologics CDMO Award: Fill-Finish' category is an award given to companies with the best quality control and technology in sterile filling and packaging. STGenBio has been highly praised for its advanced charging infrastructure, global GMP certification, and stable charging capabilities.
Estizen Bio acquired global GMP certification such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) last year, and the award will solidify its position as a next-generation global CMO that combines technology and growth potential.
APBCEA, hosted by IMAPAC, is an authoritative event that officially recognizes the achievements and innovations of the CDMO industry in the Asia-Pacific region. In particular, it is considered a place where brand trust and position in the market are evaluated as winners are selected through industrial voting.
CEO Choi Kyung-eun, who participated in the APBCEA on this day, also announced the company's technology and potential through active exchanges with global bio companies.
Choi Kyung-eun, CEO of STGenBio, said, `This award is significant in that STGenBio has proven both its potential and technological competitiveness to become a next-generation global CMO.' and'We will continue to expand the global market by providing the highest level of service based on customer trust.'
This article was translated by Naver AI translator.
